安科生物
(300009)
| 流通市值：98.96亿 | | | 总市值：134.32亿 |
| 流通股本：12.31亿 | | | 总股本：16.71亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,097,894,716.88 | 541,715,939.09 | 2,646,519,767.58 | 1,962,590,112.69 |
| 营业总成本 | 723,615,315.46 | 352,814,069.35 | 1,835,649,613.89 | 1,345,964,715.95 |
| 其他经营收益 | | | | |
| 营业利润 | 391,889,610.82 | 197,249,290.02 | 836,961,059.85 | 649,500,746.76 |
| 利润总额 | 390,387,621.58 | 197,130,921.63 | 833,158,101.19 | 648,684,249.94 |
| 净利润 | 340,305,904.64 | 172,164,747.08 | 747,338,705.69 | 562,621,438.07 |
| 每股收益 | | | | |
| 其他综合收益 | -220,259,779.45 | 22,265,954.79 | 64,761,046.22 | -78,746,995.87 |
| 综合收益总额 | 120,046,125.19 | 194,430,701.87 | 812,099,751.91 | 483,874,442.2 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,241,743,572.08 | 2,509,560,160.35 | 2,395,074,344.11 | 2,293,623,522.18 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,884,413,168.4 | 3,155,044,873.52 | 3,152,579,064.69 | 2,807,000,688.38 |
| 资产总计 | 5,126,156,740.48 | 5,664,605,033.87 | 5,547,653,408.8 | 5,100,624,210.56 |
| 流动负债: | | | | |
| 流动负债合计 | 556,799,472.62 | 583,545,020.4 | 639,700,218.06 | 606,627,204.9 |
| 非流动负债: | | | | |
| 非流动负债合计 | 157,650,379.18 | 176,524,942.56 | 171,596,553.78 | 149,015,505.62 |
| 负债合计 | 714,449,851.8 | 760,069,962.96 | 811,296,771.84 | 755,642,710.52 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,259,640,071.62 | 4,743,448,300.42 | 4,558,015,051.29 | 4,168,905,179.47 |
| 股东权益合计 | 4,411,706,888.68 | 4,904,535,070.91 | 4,736,356,636.96 | 4,344,981,500.04 |
| 负债和股东权益合计 | 5,126,156,740.48 | 5,664,605,033.87 | 5,547,653,408.8 | 5,100,624,210.56 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,114,823,467.92 | 517,150,456.19 | 2,550,989,495.9 | 1,963,442,909.04 |
| 经营活动现金流出小计 | 842,326,584.35 | 376,319,786.38 | 1,687,769,024.88 | 1,407,604,611.42 |
| 经营活动产生的现金流量净额 | 272,496,883.57 | 140,830,669.81 | 863,220,471.02 | 555,838,297.62 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,156,862,238.45 | 966,672,649.37 | 1,191,695,413.87 | 1,015,462,784.32 |
| 投资活动现金流出小计 | 966,665,495.41 | 1,131,354,346.25 | 1,644,696,180.53 | 1,226,809,235.8 |
| 投资活动产生的现金流量净额 | 190,196,743.04 | -164,681,696.88 | -453,000,766.66 | -211,346,451.48 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 70,967,920.89 | - | 30,991,248.28 | 33,991,248.28 |
| 筹资活动现金流出小计 | 490,704,941.37 | 51,679,296.35 | 494,719,869.16 | 486,888,523.67 |
| 筹资活动产生的现金流量净额 | -419,737,020.48 | -51,679,296.35 | -463,728,620.88 | -452,897,275.39 |
| 汇率变动对现金及现金等价物的影响 | -548,881.03 | -166,960.35 | -6,894,791.48 | -3,069,341.75 |
| 现金及现金等价物净增加额 | 42,407,725.1 | -75,697,283.77 | -60,403,708 | -111,474,771 |
| 期末现金及现金等价物余额 | 280,608,952.07 | 162,503,943.2 | 238,201,226.97 | 187,130,163.97 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 42,407,725.1 | - | -60,403,708 | - |